# Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer

> **NCT03367182** · — · COMPLETED · sponsor: **Yonsei University** · enrollment: 50 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Weekly paclitaxel
- **DRUG:** Topotecan
- **DRUG:** Pegylated liposomal doxorubicin
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT03367182
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-01
- **Primary completion:** 2018-01-31
- **Final completion:** 2018-01-31
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2019-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03367182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03367182, "Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03367182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*